A Prospective Real World Evidence Study aims to check how well a blood test called Episwitch CiRT® predicts if cancer patients will respond to special cancer drugs known as PD-(L)-1 checkpoint inhibitors. These drugs help the immune system fight cancer.

Episwitch CiRT® gives a result showing a high or low chance of responding to these treatments. Patients with stage III or IV cancer, who plan to start or are already on these treatments, can take this test. If they have a high chance of response, they will be retested every three months. The study lasts up to six months, tracking treatment results and patients' health progress.

Key Points:

• The study lasts six months and includes retesting every three months.
• Participants must have stage III or IV cancer and be eligible for immune therapy.
• Pregnant women, breastfeeding women, and those with certain medical histories cannot join.

The study also collects detailed health and social data to see if other factors affect treatment success. Participation involves regular health checks and filling out questionnaires.